UAE – Mubasher: Mubadala Investment Company teamed up with CBC Group, Asia's largest healthcare-dedicated asset management group, to acquire the carve-out of UCB Pharma’s mature business in China.
Besides its expansion in immunology, neurology and rare disease market, UCB is strategically poised for growth in its Central Nervous System (CNS) originator drug portfolio, according to a press release.
This acquisition includes UCB’s neurology portfolio and allergy portfolio in Mainland China, as well as UCB’s Zhuhai manufacturing site.
Meanwhile, the transaction is subject to certain closing conditions, including required anti-trust clearance(s) and other customary conditions. It is expected to close in the fourth quarter (Q4) of 2024.
This investment aligns with Mubadala’s vision to expand its footprint across Asia through selective investment across diverse sectors with strong growth potential.
Mina Hamoodi, Head of Healthcare at Mubadala, commented: “CNS is a large and growing therapeutic area in China that has an urgent clinical need. We look forward to building out a broader CNS-focused platform to benefit the China market.”
Jean-Christophe Tellier, CEO at UCB, said: "In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China."
Jean-Christophe added: “We are convinced that Mubadala and CBC Group are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China."
Last March, Mubadala fully acquired the pan-African biopharmaceuticals platform KELIX bio.
